EP1971353A2 - Compositions cosmetiques a base d'huiles essentielles et leur utilisation dans le soulagement des douleurs - Google Patents
Compositions cosmetiques a base d'huiles essentielles et leur utilisation dans le soulagement des douleursInfo
- Publication number
- EP1971353A2 EP1971353A2 EP06831656A EP06831656A EP1971353A2 EP 1971353 A2 EP1971353 A2 EP 1971353A2 EP 06831656 A EP06831656 A EP 06831656A EP 06831656 A EP06831656 A EP 06831656A EP 1971353 A2 EP1971353 A2 EP 1971353A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions according
- lavender
- compositions
- plantain
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 239000000341 volatile oil Substances 0.000 title claims abstract description 34
- 239000002537 cosmetic Substances 0.000 title claims abstract description 6
- 244000178870 Lavandula angustifolia Species 0.000 claims abstract description 13
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims abstract description 13
- 239000001102 lavandula vera Substances 0.000 claims abstract description 13
- 235000018219 lavender Nutrition 0.000 claims abstract description 13
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 10
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 10
- 244000301850 Cupressus sempervirens Species 0.000 claims abstract description 7
- 241000208152 Geranium Species 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 239000000499 gel Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 241000234295 Musa Species 0.000 claims description 9
- 240000000103 Potentilla erecta Species 0.000 claims description 8
- 229940098465 tincture Drugs 0.000 claims description 8
- 239000003981 vehicle Substances 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- 230000003902 lesion Effects 0.000 claims description 7
- 210000004400 mucous membrane Anatomy 0.000 claims description 7
- 241000366182 Melaleuca alternifolia Species 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 235000016551 Potentilla erecta Nutrition 0.000 claims 2
- 229940087164 tormentil Drugs 0.000 claims 2
- 230000035876 healing Effects 0.000 abstract description 3
- 206010040882 skin lesion Diseases 0.000 abstract description 2
- 231100000444 skin lesion Toxicity 0.000 abstract description 2
- 241000378467 Melaleuca Species 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 208000004898 Herpes Labialis Diseases 0.000 description 11
- 206010067152 Oral herpes Diseases 0.000 description 11
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 229960004150 aciclovir Drugs 0.000 description 6
- -1 Aciclovir monophosphate Chemical class 0.000 description 5
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 4
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N beta-linalool Natural products CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Natural products CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 3
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- YKFLAYDHMOASIY-UHFFFAOYSA-N terpinene-gamma Natural products CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 3
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- WRYLYDPHFGVWKC-JTQLQIEISA-N (R)-(-)-p-Menth-1-en-4-ol Natural products CC(C)[C@@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-JTQLQIEISA-N 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 2
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- BQOFWKZOCNGFEC-UHFFFAOYSA-N carene Chemical compound C1C(C)=CCC2C(C)(C)C12 BQOFWKZOCNGFEC-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- 229930006696 sabinene Natural products 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- FUCYIEXQVQJBKY-ZFWWWQNUSA-N (+)-δ-Cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(C)=C21 FUCYIEXQVQJBKY-ZFWWWQNUSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N Citronellol Natural products OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Natural products COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GLZPCOQZEFWAFX-UHFFFAOYSA-N KU0063794 Natural products CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- GJJYQFPADNKBDY-UHFFFAOYSA-N Sabinol Natural products C=C1CCC2(C(C)C)C1(O)C2 GJJYQFPADNKBDY-UHFFFAOYSA-N 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- UIDUJXXQMGYOIN-UHFFFAOYSA-N aromadendrin Natural products CC1(C)C2C1CCC(C)C1C2C(C)CC1 UIDUJXXQMGYOIN-UHFFFAOYSA-N 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- 229940026455 cedrol Drugs 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229930007927 cymene Natural products 0.000 description 1
- YOCDGWMCBBMMGJ-UHFFFAOYSA-N delta-cadinene Natural products C1C=C(C)CC2C(C(C)C)CCC(=C)C21 YOCDGWMCBBMMGJ-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- WRHGORWNJGOVQY-RRFJBIMHSA-N gamma-Muurolene Natural products C1CC(C)=C[C@@H]2[C@H](C(C)C)CCC(=C)[C@H]21 WRHGORWNJGOVQY-RRFJBIMHSA-N 0.000 description 1
- JBHJOURGKXURIW-UHFFFAOYSA-N gamma-cadinene Natural products CC(C)C1CCC(=C2CCC(=C)CC12)C JBHJOURGKXURIW-UHFFFAOYSA-N 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- WRHGORWNJGOVQY-ZNMIVQPWSA-N gamma-muurolene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(=C)[C@H]21 WRHGORWNJGOVQY-ZNMIVQPWSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the present invention relates to the necessities of life, more particularly to the field of cosmetology and dermatology.
- It relates more particularly to the field of phytotherapy and aromatherapy.
- the subject of the invention is specifically cosmetic compositions, and more specifically phytotherapeutic compositions based on a mixture of essential oils intended to relieve pain, and to facilitate the repair and treatment of dermal tissues damaged by the manifestations.
- cold sores such as cold sores.
- Herpes labialis is caused mainly by the herpes simplex virus type 1. It is classically called cold sore. It is the most common form of herpes.
- herpes simplex virus type 1 In their lifetime, 90% of all subjects come into contact with the herpes simplex virus type 1, most often before the second year of life. Viruses get into the body through the skin or mucous membranes. Contamination can occur from the first contact with an affected person. However, this primary infection often goes unnoticed or is manifested by herpetic gingivostomatitis (a foul smell of breath in children). Once the virus is installed in the human body, it persists for life. After primary infection, the viruses are stored in the nerve ganglia and can remain inactive for years without being detected by the immune system.
- aciclovir results from the blocking of viral replication by inhibiting its DNA polymerase.
- Aciclovir monophosphate is also incorporated into the viral chain, putting an end to its elongation.
- the virus stored in the ganglia are removed from the action of aciclovir and therefore are not destroyed.This is why after stopping treatment, a herpes outbreak can occur at any time.
- the level of effectiveness is even more important that the drug is applied early, before the manifestation of clinical signs, which of course is hardly feasible or even feasible.
- aciclovir prevents replication of the virus but does not support local skin lesions caused by herpes, and that it does not eradicate herpes disease in a subject: intracellular "reservoir" viruses can to manifest at any time.
- dermatoses are often over-infected by certain germs that develop in quantity, while breaking the local skin balance. There is a possibility of superinfection of the herpes lesion area. Various bacteria or Candida fungi can be found.
- compositions which are the subject of the invention are intended to promote the repair of damaged tissues, an aspect not supported by the antiviral treatment, while acting on the painful consequences of cold sores.
- compositions consist of a mixture of vegetable essential oils of plants. They consist more precisely of a mixture consisting of four essential oils and two mother tinctures.
- the essential oils of plants have an immediate effect on the superficial blood circulation. They are therefore able to accelerate the efficiency of the drainage of damaged tissues.
- the draining and anti-inflammatory properties of some essential oils help to reduce the local compression of nerve endings, which causes pain.
- compositions which are the subject of the invention not only for the adjunctive treatment of cold sores, but also for any type of labial and peri-labial lesions, as well as for the small affections of the herpes labialis. mouth of the mouth ulcer type.
- the essential oils are devoid, compared to conventional antiviral and antimicrobial drugs, microbial or viral resistance effect and any addiction of germs to these essential oils, which allows frequent use, particularly suitable for recurrent herpes outbreaks.
- compositions which are the subject of the invention comprise plants in another stabilized form: the mother tinctures.
- mother tinctures the methods for obtaining and controlling mother tinctures are described in the European Pharmacopoeia, allowing the use of constant products. These are alcoholic extracts.
- the cutaneous lesions are sensitive to light and in particular lesions of herpetic origin. It is thus recommended to protect the injured areas from sun exposure and in particular from UV rays. As a result, it will be useful to include the compositions a sun filter UV.
- the invention therefore consists of a mixture of several essential oils and mother tinctures, characterized in that the mixture contains the following active ingredients:
- Sesquiterpenes beta-caryophyllene, alpha-humolene, gamma-muurolene, delta-cadinene, germacrene-D-
- aucubine has antibacterial properties, conferred by the aucubine it contains, hence a common use in skin inflammation. Its main components are: aucubine
- active ingredients are incorporated in a water-alcoholic excipient suitable for the topical route, that is to say the local application on the skin (cutaneous application) and the mucous membranes.
- a suitable solution consists in obtaining a composition of semi-liquid consistency.
- the excipient used is a mixture of acrylic acid polymer, water and alcohol.
- the acrylic acid polymer is a product of the range sold under the brand name "CARBOPOL®” (Goodrich).
- a sunscreen may be added to the excipient gel, such as Parsol® MCX, in proportions varying preferably from 0.1 to 7% by weight relative to the composition of the gel.
- compositions flavoring or odoriferous natural or artificial substances, in order to make the application of the product more pleasant.
- a solution of choice for this problem is to use, in replacement of the mother tinctures, alcohol-free plant extracts such as hydro-glycolic extracts of plants; it is also possible to reduce the content of the compositions to Lavender alcoholate and / or to replace the alcohol at 96 ° or 60 ° used as an excipient with alcohol at 20 °.
- compositions according to the invention are intended for use by topical application at a rate of one to several applications per day on the injured areas.
- the active products consisting of the essential oils and the mother tinctures are first mixed. This mixture is then incorporated into the hydroalcoholic excipient to obtain the desired fluidity.
- a gel whose initial formula is defined as follows can be used as a hydroalcoholic excipient:
- the mother tinctures are replaced by hydro-glycolic extracts, and the desired consistency of the hydroalcoholic excipient gel is obtained using alcohol at 20 ° instead of the alcohol at 96 ° or 60 ° C. °.
- Geranium essential oil 0.5% to 25%
- Example 3 formulation including aromas
- Example 4 Process for producing the compositions according to the invention
- the starting tincture is the mother tinctures or the hydro-glycolic extracts of Plantain and Tormentille. After homogenization by stirring, the four essential oils are incorporated one after the other, stirring the mixture between each addition.
- the above-defined mixture is incorporated in a hydrophilic vehicle, in particular a hydroalcoholic gel, avoiding the inclusion of air bubbles in the composition.
- the gelling product is a carbomer gel, or polyacrylamide, or cellulose derivative.
- the hydroalcoholic gel has the formula defined as follows:
- a sufficient and appropriate amount of alcohol is added at 96 °, 60 ° or 20 °.
- the packaging must be adapted to the mode of application to the skin, as well as to the consistency defined for the compositions (fluid, semi-solid, solid), such as ointments, creams, gels, water-in-silicone emulsions, oil-in-water emulsions, water-in-oil emulsions, or liposomes.
- compositions comprising a significant amount of volatile products, it is necessary to ensure a good seal capping system.
- compositions comprising essential oils and extracts of plants sensitive to light, should be used containers or opaque packaging.
- a semi-solid consistency such as a gel
- it may be used for example a packaging consisting of a stick provided with a metal rollerball. This ball makes it possible to regulate the flow and to ensure a measured delivery of the product.
- a metal ball coated with a gold film is used. This avoids any potential allergies due to contact with nickel may enter the composition of the metal ball.
- the very high thermal conductivity of gold allows, when applied to the herpes zone, to increase the freshness effect induced by the gel, by promoting the caloric pumping at the level of the lesion.
- a container provided with a free end for direct application of the product, such as a stick lip.
- Another suitable packaging and allowing the single use is the wipe, which is soaked compositions according to the invention before packaging in aluminum foil to have a sealed package.
- the active ingredients constituted by essential oils are those defined in the monographs provided for by the European Pharmacopoeia.
- Thin layer chromatography and gas chromatogram examination appear as analytical techniques of choice for checking the sample composition of the mixture.
- the physical properties in particular the fluidity and the viscosity, are evaluated according to the conventional control methods.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0512618A FR2894483B1 (fr) | 2005-12-13 | 2005-12-13 | Composition cosmetique a base d'huiles et leurs utilisations dans le soulagement des douleurs. |
PCT/IB2006/003502 WO2007069015A2 (fr) | 2005-12-13 | 2006-12-07 | Compositions cosmetiques a base d'huiles essentielles et leur utilisation dans le soulagement des douleurs |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1971353A2 true EP1971353A2 (fr) | 2008-09-24 |
Family
ID=36794456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06831656A Withdrawn EP1971353A2 (fr) | 2005-12-13 | 2006-12-07 | Compositions cosmetiques a base d'huiles essentielles et leur utilisation dans le soulagement des douleurs |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1971353A2 (fr) |
FR (1) | FR2894483B1 (fr) |
WO (1) | WO2007069015A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0700426A2 (en) * | 2007-06-19 | 2010-03-29 | Invencio 21 Gyogyhatasu Keszit | Liposomal compound |
CN104188882A (zh) * | 2014-08-21 | 2014-12-10 | 青岛蓝图文化传播有限公司市南分公司 | 一种含有莳萝精油的护肤霜 |
CN104146917A (zh) * | 2014-08-21 | 2014-11-19 | 青岛蓝图文化传播有限公司市南分公司 | 一种可止痛的护肤奶液 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4418976C2 (de) * | 1994-05-31 | 1996-12-12 | Horst Walter Hendricks | Phytotherapeutikum zur Behandlung von Infektionen des Herpes simplex-Virus (Typ 1 und Typ 2) und Verfahren zu seiner Herstellung |
FR2744634B1 (fr) * | 1996-02-13 | 1998-03-20 | Boiron | Gel labial comprenant un melange d'extraits alcooliques de plantes |
EP1011609A4 (fr) * | 1997-05-09 | 2000-08-16 | Medlogic Global Corp | Compositions pour applications cosmetiques |
US20020082279A1 (en) * | 1999-10-15 | 2002-06-27 | Neal B. Schultz | Method and composition for the treatment of dermatologic diseases |
US6967023B1 (en) * | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
WO2003021515A2 (fr) * | 2001-08-30 | 2003-03-13 | Cheryl Sott | Procede, appareil, et systeme pour la personnalisation d'huiles essentielles et d'autres formulations |
KR100489934B1 (ko) | 2002-07-16 | 2005-05-17 | 허행조 | 에너지 절약형 전기 보일러 |
EP1539204A1 (fr) * | 2002-08-30 | 2005-06-15 | Biopharmacopae Design International Inc. | Extraits vegetaux pour le traitement de l'angiogenese et de la metastase |
JP2004269430A (ja) * | 2003-03-10 | 2004-09-30 | Ichimaru Pharcos Co Ltd | 毛髪処理用組成物及び損傷毛用毛髪化粧料 |
AU2004220541B2 (en) * | 2003-03-12 | 2009-03-26 | Epitome Pharmaceuticals Limited | Rapidly absorbing lipophilic skin compositions and uses therefor |
-
2005
- 2005-12-13 FR FR0512618A patent/FR2894483B1/fr not_active Expired - Fee Related
-
2006
- 2006-12-07 WO PCT/IB2006/003502 patent/WO2007069015A2/fr active Application Filing
- 2006-12-07 EP EP06831656A patent/EP1971353A2/fr not_active Withdrawn
Non-Patent Citations (11)
Title |
---|
ABU ALI LBN-E-SINA: "Al-Qaanoon-fil-Tibb", vol. V, 1996, pages: 154 |
ALI LBN-E-ABBAAS MAJOOSI: "Kaamil-al-Sena'ah", 2005, pages: 584 |
DATABASE TKDL [online] "Dohn-e-Hindi", XP003029754, Database accession no. AH2/378 |
DATABASE TKDL [online] "Kamaad Bara-e-Dard-e-Zarbah", XP003029755, Database accession no. AH5/2723 |
DATABASE TKDL [online] "Natool-e-Ustukhuddus", XP003029752, Database accession no. NA2/103H |
DATABASE TKDL [online] "Takmeed-e-Mumsikul Arwaah", XP003029753, Database accession no. MH3/109X |
DATABASE TKDL [online] "Zimaad Barae Raz-wa-Zarba", XP003029756, Database accession no. AH3/4843 |
MOHAMMAD AKMAL KHAN: "Qaraabaadeen Azam wa Akmal", 1909, pages: 593 |
MOHAMMAD AZAM KHAN: "Muheet-e-Azam", vol. I, 1896, pages: 151 |
MOHAMMAD NAJMUL GHANI KHAN: "Khazaain-al-Advia", vol. I, 1911, pages: 494 |
See also references of WO2007069015A2 |
Also Published As
Publication number | Publication date |
---|---|
FR2894483A1 (fr) | 2007-06-15 |
FR2894483B1 (fr) | 2008-05-02 |
WO2007069015A2 (fr) | 2007-06-21 |
WO2007069015A3 (fr) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0022046B1 (fr) | Nouvelle composition médicamenteuse à base de plantes et procédé de préparation | |
Aslani et al. | Design, formulation, and evaluation of a herbal gel contains melissa, sumac, licorice, rosemary, and geranium for treatment of recurrent labial herpes infections | |
EP1814564B1 (fr) | Dispositif d'administration transmucosale | |
US20220110993A1 (en) | Compositions for treatment of jaw pain, temporomandibular joint and muscle disorder and bruxism | |
EP1971353A2 (fr) | Compositions cosmetiques a base d'huiles essentielles et leur utilisation dans le soulagement des douleurs | |
WO2012007670A2 (fr) | Composition cosmetique ou dermatologique et son utilisation, pour le soin de la peau des hommes jeunes | |
CA2627021A1 (fr) | Formulation topique de source naturelle/anesthesiant local/compose ameliorant la penetration utile pour le traitement de la douleur, du prurit et/ou d'une inflammation cutanee | |
FR3091819A1 (fr) | Composition pour le traitement et/ou la prevention des symptomes du bas appareil urinaire | |
WO2009010587A1 (fr) | Utilisation d'au moins un extrait de parties aériennes de l'epilobe et/ou de l'onagre pour la préparation d'une composition destinée à restaurer la fonction barrière des tissus kératinisés ou des muqueuses. | |
WO2006042928A1 (fr) | Composition pour prevenir ou traiter le stress, notamment les bouffees de stress chronique et permanent | |
WO2022175434A2 (fr) | Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements | |
WO2020221979A1 (fr) | Nouvelle formulation topique modulant les voies de la nociception | |
WO2006111844A1 (fr) | Utilisation de l'azithromycine pour la fabrication d'un medicament de traitement des infections oculaires | |
WO2013088063A1 (fr) | Composition cosmetique comprenant du miel de thym et de l'eau thermale de neyrac | |
EP2258354B1 (fr) | Composés et méthodes pour contrôler la prise d'alcool. | |
FR3140537A1 (fr) | Dispositif médical apte à couvrir l’ongle d’un orteil ou d’un doigt | |
EP2811978B1 (fr) | Utilisation d'un extrait d'ecorce de pommier dans une composition cosmetique anti-age | |
CA2725770A1 (fr) | Compositions a base de plantes et utilisations | |
US20210338756A1 (en) | Healing creams and formulations containing pomegranate seed oil, rosa canina fruit oil, inula viscosa oleoresin or extract and optionally citrus medica vulgaris etrog oil or extract | |
US20210030698A1 (en) | Gel containing zerumbone from bitter ginger (zingiber zerumbet) for curative treatment of diabetic ulcers | |
FR2622800A1 (fr) | Procede de preparation d'un produit de lutte contre des affections virales en particulier des affections virales cutaneo-muqueuses,compositions pharmaceutiques et medicaments obtenus a partir de ce procede | |
WO2013117866A2 (fr) | Utilisation d'un extrait de feuille de pommier dans une composition cosmetique pour le raffermissement de la peau | |
WO2023180981A1 (fr) | Extrait de melaleuca alternifolia et ses utilisations cosmétiques | |
WO2005018655A1 (fr) | Utilisation du noni lors de pathologies bucco dentaires notamment pour combattre les problemes d’asialie et d’hyposialie | |
TR2021007003A2 (tr) | Nazal ve oral kullanima yöneli̇k anti̇vi̇ral ve anti̇bakteri̇yel etki̇li̇ lavanta, sedi̇r, ci̇tronella, nane, palmarosa, karanfi̇l, selvi̇ ve li̇mon uçucu yağlari i̇çeren bi̇tki̇sel bi̇r kompozi̇syon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
17P | Request for examination filed |
Effective date: 20080711 |
|
17Q | First examination report despatched |
Effective date: 20091117 |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DEYLON SARL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140701 |